Основная статистика
| CIK | 1630627 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Treace Medical Concepts, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 7, 2025 |
Incentive Letter Agreement between Treace Medical Concepts, Inc. and Gaetano M. Guglielmino EXHIBIT 10.1 Certain identified information in this document has been omitted in accordance with Item 601(b)(10) of Regulation S-K because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. February 4, 2025 To: Guy Guglielmino Guy, We are pleased to share that the Compensation Committee o |
|
| August 7, 2025 |
inno00."333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-4035 |
|
| August 7, 2025 |
Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2025 Financial Results Announces Full Market Release of Three New Bunion Technologies PONTE VEDRA, Fla. – August 7, 2025 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Treace Medical Concepts, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0 |
|
| May 9, 2025 |
As filed with the Securities and Exchange Commission on May 9, 2025 As filed with the Securities and Exchange Commission on May 9, 2025 Registration No. |
|
| May 8, 2025 |
00."333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 T |
|
| May 8, 2025 |
Exhibit 10.2 amendment No. 2 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of April 24, 2025, by and among TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), MidCap Financial Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assigns, “Agent”) |
|
| May 8, 2025 |
Incentive Letter Agreement between Treace Medical Concepts, Inc. and Scot M. Elder EXHIBIT 10.3 Certain identified information in this document has been omitted in accordance with Item 601(b)(10) of Regulation S-K because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. November 11, 2024 Scot Elder Via Email Dear Scot, As an incentive to you to maintain your employmen |
|
| May 8, 2025 |
Treace Medical Concepts Reports First Quarter 2025 Financial Results Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2025 Financial Results PONTE VEDRA, Fla. – May 8, 2025 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported fin |
|
| May 8, 2025 |
EXHIBIT 10.1 amendment No. 2 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 2 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of April 24, 2025, by and among TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), MidCap Funding IV Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors and assign |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commissi |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commis |
|
| April 7, 2025 |
Treace Announces Upcoming Board Chair Transition Exhibit 99.1 Treace Announces Upcoming Board Chair Transition PONTE VEDRA, Fla., April 7, 2025 - Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Dir |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Co |
|
| February 27, 2025 |
EXHIBIT 10.6 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of December 4, 2024, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and GAETANO GUGLIELMINO (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Con |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40355 TREACE MEDICAL |
|
| February 27, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 INSIDER TRADING COMPLIANCE POLICY Table of Contents 1. PURPOSE AND SCOPE. 1 2. DEFINITIONS. 2 3. EXECUTIVE SUMMARY. 3 3.1 ROLES AND RESPONSIBILITIES 3 3.2 KEY POINTS 3 4. POLICY STATEMENT (DETAILS). 3 5. REFERENCES, RELATED POLICIES, & FAQ 8 1. Purpose and Scope. Purpose: Federal laws and regulations prohibit trading in the securities of a company while in possession of material nonpu |
|
| February 27, 2025 |
Non-Employee Director Compensation Program Exhibit 10.15 Treace Medical Concepts, Inc. Non-Employee Director Compensation Program Amended and Restated as of January 17, 2024 and amended as of August 1, 2024 and February 19, 2025 This Treace Medical Concepts, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) was adopted under the Company’s 2021 Incentive Award Plan (the “2021 Plan”) effective as of the closing |
|
| February 27, 2025 |
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results PONTE VEDRA, Fla. – February 27, 2025 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedure |
|
| January 13, 2025 |
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue Exhibit 99.1 Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue PONTE VEDRA, Florida, January 13, 2025- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| January 13, 2025 |
Investor Presentation January 2025 On solid footing for sustained growth 1 Exhibit 99. |
|
| November 14, 2024 |
TMCI / Treace Medical Concepts, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-tmci093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TREACE MEDICAL CONCEPTS, INC. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 89455T109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 7, 2024 |
TMCI / Treace Medical Concepts, Inc. / Treace John T. - SC 13G/A Passive Investment SC 13G/A 1 jttreacesched13ganov2024.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Treace Medical Concepts, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89455T109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 0."333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-4035 |
|
| November 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| November 5, 2024 |
Treace Medical Concepts Reports Third Quarter 2024 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Third Quarter 2024 Financial Results PONTE VEDRA, Fla. – November 5, 2024 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reporte |
|
| October 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| October 15, 2024 |
Exhibit 99.1 Treace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty® Bunion Technology PONTE VEDRA, Fla., October 14, 2024 - Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductop |
|
| August 6, 2024 |
Treace Medical Concepts Reports Second Quarter 2024 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2024 Financial Results PONTE VEDRA, Fla. – August 6, 2024 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported |
|
| August 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q "333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Treac |
|
| May 22, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Treace Medical Concepts, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0 |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 7, 2024 |
Treace Medical Concepts Reports First Quarter 2024 Financial Results Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2024 Financial Results PONTE VEDRA, Fla. – May 7, 2024 – Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today reported fin |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q "333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Trea |
|
| May 7, 2024 |
First Quarter 2024 Earnings Presentation May 7, 2024 On solid footing for sustained top-tier growth 1 This presentation may include forward- looking statements. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commissi |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| February 27, 2024 |
Fourth Quarter 2023 Earnings Presentation February 27, 2024 On solid footing for sustained top-tier growth 1 EX-99. |
|
| February 27, 2024 |
Exhibit 99.1 Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance PONTE VEDRA, Fla. – February 27, 2024 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® a |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Co |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40355 TREACE MEDICAL |
|
| February 27, 2024 |
Non-Employee Director Compensation Policy Exhibit 10.14 Treace Medical Concepts, Inc. Non-Employee Director Compensation Program Amended and Restated as of January 17, 2024 This Treace Medical Concepts, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) was adopted under the Company’s 2021 Incentive Award Plan (the “2021 Plan”) effective as of the closing of the Company’s initial public offering of its common |
|
| February 27, 2024 |
Policy For Recovery of Erroneously Awarded Compensation Exhibit 97.1 TREACE MEDICAL CONCEPTS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Treace Medical Concepts, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons S |
|
| February 14, 2024 |
TMCI / Treace Medical Concepts, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Treace Medical Concepts Inc (Name of Issuer) Common Stock (Title of Class of Securities) 89455T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2024 |
TMCI / Treace Medical Concepts, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02105-treacemedicalconcept.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Treace Medical Concepts Inc Title of Class of Securities: Common Stock CUSIP Number: 89455T109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate bo |
|
| February 9, 2024 |
TMCI / Treace Medical Concepts, Inc. / Treace John T. - SC 13G/A Passive Investment SC 13G/A 1 jttreacesched13gafeb2024.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities ExchangeAct of 1934 (Amendment No. 2)* Treace Medical Concepts, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 89455T109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement |
|
| January 10, 2024 |
42nd Annual J.P. Morgan Healthcare Conference John T. Treace, CEO & Founder January 9, 2024 On solid footing for sustained top-tier growth 1 This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, strategy and plans, ind |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Comm |
|
| January 8, 2024 |
Exhibit 99.1 Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue Company to Present at J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 3:45 pm Pacific Time PONTE VEDRA, Fla. – January 8, 2024 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2023 |
Form of Performance Stock Unit Award For Employees under 2021 Incentive Award Plan Exhibit 10.1 TREACE MEDICAL CONCEPTS, INC. 2021 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD GRANT NOTICE Treace Medical Concepts, Inc., a Delaware corporation, (the “Company”), pursuant to its 2021 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an award of restricted stock units that vest based (in part) on achieveme |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q “333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 |
|
| November 9, 2023 |
Treace Medical Concepts Reports Third Quarter 2023 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Third Quarter 2023 Financial Results PONTE VEDRA, Fla. – November 9, 2023 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported fin |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q “333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Treac |
|
| August 8, 2023 |
Treace Medical Concepts Reports Second Quarter 2023 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2023 Financial Results PONTE VEDRA, Fla. – August 8, 2023 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ Procedure, today reported fina |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commis |
|
| June 13, 2023 |
Exhibit 99.1 Treace Medical Completes Acquisition of Technology Enabling Patient Specific Instrumentation and Reports on Clinical Cases Using PSI with the Lapiplasty® System PONTE VEDRA, Fla., June 13, 2023 - Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known |
|
| June 1, 2023 |
JUNE 1, 2023 Forward Looking Statements and Other Cautions This presentation may include forward- looking statements. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commiss |
|
| June 1, 2023 |
Exhibit 99.2 Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries PONTE VEDRA, Fla. – June 1, 2023—Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has sign |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commiss |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q “333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Trea |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commissi |
|
| May 8, 2023 |
Treace Medical Concepts Reports First Quarter 2023 Financial Results Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2023 Financial Results PONTE VEDRA, Fla. – May 8, 2023 — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2023. Re |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40355 47-1052611 (State or Other Jurisdiction of Incorporation) (Commi |
|
| March 8, 2023 |
As filed with the Securities and Exchange Commission on March 8, 2023 S-8 As filed with the Securities and Exchange Commission on March 8, 2023 Registration No. |
|
| March 8, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Treace Medical Concepts, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Fees to Be Paid |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40355 TREACE MEDICAL |
|
| March 8, 2023 |
Non-Employee Director Compensation Policy Exhibit 10.14 Treace Medical Concepts, Inc. Non-Employee Director Compensation Program Amended and Restated December 13, 2022, as amended on January 20, 2023 This Treace Medical Concepts, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) was adopted under the Company’s 2021 Incentive Award Plan (the “2021 Plan”) effective as of the closing of the Company’s initial pu |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commis |
|
| March 7, 2023 |
Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results PONTE VEDRA, Fla. – March 7, 2023—Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40355 47-1052611 (State or Other Jurisdiction of Incorporation) (Co |
|
| February 14, 2023 |
TMCI / Treace Medical Concepts, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Treace Medical Concepts Inc (Name of Issuer) Common Stock (Title of Class of Securities) 89455T109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 13, 2023 |
TMCI / Treace Medical Concepts, Inc. / TREACE JOHN R - SC 13G/A Passive Investment SC 13G/A 1 d405922dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Treace Medical Concepts, Inc. (Name of Issuer) Common Stock, $0.001 par va |
|
| February 13, 2023 |
TMCI / Treace Medical Concepts, Inc. / Treace John T. - SC 13G/A Passive Investment SC 13G/A 1 d416669dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Treace Medical Concepts, Inc. (Name of Issuer) Common Stock, $0.001 par va |
|
| February 10, 2023 |
Exhibit 1.1 Treace Medical Concepts, Inc. 4,761,905 Shares of Common Stock, par value $0.001 per share Underwriting Agreement February 7, 2023 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, Ne |
|
| February 10, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 10, 2023 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) 001-40355 (Commission File Number) Delaware 47-1052611 (State or other jurisdict |
|
| February 9, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Treace Medical Concepts, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fe |
|
| February 9, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269622 Prospectus Supplement (To Prospectus Dated February 7, 2023) 4,761,905 Shares Common Stock We are offering 4,761,905 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol “TMCI.” The last reported sale price of our common stock on the Nasdaq Global Select Market on Fe |
|
| February 9, 2023 |
TMCI / Treace Medical Concepts, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Treace Medical Concepts Inc. Title of Class of Securities: Common Stock CUSIP Number: 89455T109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| February 7, 2023 |
Subject to completion, dated February 7, 2023 Table of Contents The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| February 7, 2023 |
Exhibit 4.3 TREACE MEDICAL CONCEPTS, INC. INDENTURE Dated as of , 20 Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| February 7, 2023 |
As filed with the Securities and Exchange Commission on February 7, 2023 Table of Contents As filed with the Securities and Exchange Commission on February 7, 2023 Registration No. |
|
| February 7, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Treace Medical Concepts, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Co |
|
| January 9, 2023 |
Treace Medical Concepts Provides 2022 Preliminary Unaudited Revenue EX-99.1 2 tmci-ex991.htm EX-99.1 Exhibit 99.1 Treace Medical Concepts Provides 2022 Preliminary Unaudited Revenue PONTE VEDRA, Fla. - January 9, 2023 (GLOBE NEWSWIRE) - Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D |
|
| January 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Comm |
|
| November 9, 2022 |
Exhibit 10.2 Execution Version amendment No. 1 to CREDIT AND SECURITY AGREEMENT (TERM LOAN) This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (TERM LOAN) (this “Agreement”) is made as of October 5, 2022, by and among TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), MidCap Financial Trust, a Delaware statutory trust, as Agent (in such capacity, together with its successors an |
|
| November 9, 2022 |
Exhibit 10.1 Execution Version amendment No. 1 to CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) This AMENDMENT NO. 1 TO CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) (this “Agreement”) is made as of October 5, 2022, by and among TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), MidCap Funding IV Trust, a Delaware statutory trust, as Agent (in such capacity, together with its su |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q “333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 |
|
| November 8, 2022 |
Treace Medical Concepts Reports Third Quarter 2022 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Third Quarter 2022 Financial Results PONTE VEDRA, Fla. ? November 8, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the third quarter ended September 30, 2 |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| September 28, 2022 |
Treace Medical Concepts Appoints New Directors Exhibit 99.1 Treace Medical Concepts Appoints New Directors PONTE VEDRA, Fla. ? September 27, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced the appointment of Lance E. Berry and Jane E. Kiernan to its board of directors, |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2022 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40355 47-1052611 (State or Other Jurisdiction of Incorporation) (C |
|
| August 10, 2022 |
Exhibit 10.2 Certain information contained in this document has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. CREDIT AND SECURITY AGREEMENT (TERM LOAN) dated as of April 29, 2022 by and among TREACE MEDICAL CONCEPTS, INC., and any additional borrower that hereaft |
|
| August 10, 2022 |
Exhibit 10.1 Certain information contained in this document has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Omitted portions are marked with “[***]” in this exhibit. CREDIT AND SECURITY AGREEMENT (REVOLVING LOAN) dated as of April 29, 2022 by and among TREACE MEDICAL CONCEPTS, INC., and any additional borrower that he |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q “333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Treac |
|
| August 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2022 |
Treace Medical Concepts Reports Second Quarter 2022 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2022 Financial Results PONTE VEDRA, Fla. ? August 9, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the second quarter ended June 30, 2022. |
|
| May 23, 2022 |
Submission of Matters to a Vote of Security Holders 0001630627false00016306272022-05-052022-05-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Treac |
|
| May 5, 2022 |
Treace Medical Concepts Reports First Quarter 2022 Financial Results Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2022 Financial Results PONTE VEDRA, Fla. ? May 5, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the first quarter ended March 31, 2022. Rece |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commissi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| May 4, 2022 |
Treace Secures Up to $150 Million in Debt Financing Treace Secures Up to $150 Million in Debt Financing PONTE VEDRA, Fla., May 2, 2022 (GLOBE NEWSWIRE) - Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced that it has entered into a new five-year $150 million loan arrangement with Mid |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 4, 2022 |
Severance Agreement with Joe W. Ferguson Exhibit 10.12 RELEASE AND CONSULTING AGREEMENT This Release and Consulting Agreement (the ?Agreement?) is entered into as of October 20, 2021 (the ?Effective Date?), by and between Treace Medical Concepts, Inc. (the ?Company?) and Joe W. Ferguson (?Ferguson?) (The Company and Ferguson sometimes referred to collectively herein as the ?Parties?). Preliminary Statement. Ferguson was employed by the C |
|
| March 4, 2022 |
Non-Employee Director Compensation Policy Exhibit 10.20 Amended and Restated Director Compensation Program Board Compensation Program - Compensation for Non-Employee Director Positions This Treace Medical Concepts, Inc. (the ?Company?) Non-Employee Director Compensation Program (this ?Program?) has been adopted under the Company?s 2021 Incentive Award Plan (the ?Plan?) and shall be effective as of the closing of the Company?s initial publ |
|
| March 4, 2022 |
Change in Control Severance Agreement by and between Treace Medical Concepts, Inc. and Scot Elder Exhibit 10.7 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of October 25, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and SCOT M. ELDER (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control ( |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40355 TREACE MEDICAL |
|
| March 4, 2022 |
As filed with the Securities and Exchange Commission on March 4, 2022 As filed with the Securities and Exchange Commission on March 4, 2022 Registration No. |
|
| March 4, 2022 |
Description of common stock of Treace Medical Concepts, Inc. Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Treace Medical Concepts, Inc. (the ?Company? or ?we? or ?our? or ?us? or ?Treace Medical Concepts?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 |
|
| March 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Treace Medical Concepts, Inc. |
|
| March 3, 2022 |
Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results PONTE VEDRA, Fla. ? March 3, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full ye |
|
| March 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commis |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Co |
|
| February 11, 2022 |
TIG / TiGenix / TREACE JOHN R - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Treace Medical Concepts, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 89457 |
|
| February 11, 2022 |
TIG / TiGenix / Treace John T. - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Treace Medical Concepts, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 89457 |
|
| January 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40355 47- 1052611 (State or other jurisdiction of incorporation) (Co |
|
| January 12, 2022 |
Treace Medical Concepts Provides 2021 Preliminary Sales Results Exhibit 99.1 Treace Medical Concepts Provides 2021 Preliminary Sales Results PONTE VEDRA, Fla. ? January 10, 2022?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today announced preliminary unaudited results for fourth qu |
|
| November 4, 2021 |
Change in Control Severance Agreement by and between Treace Medical Concepts, Inc. and Aaron Berutti EXHIBIT 10.2 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT effective as of August 3, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and AARON BERUTTI (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control (a |
|
| November 4, 2021 |
Change in control severance agreement by and between Treace Medical Concepts, Inc. and Terry Lubben Exhibit 10.3 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of September 17, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and TERRY W. LUBBEN (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Contr |
|
| November 4, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Com |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Tre |
|
| November 4, 2021 |
Treace Medical Concepts Reports Third Quarter 2021 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Third Quarter 2021 Financial Results PONTE VEDRA, Fla. ? November 4, 2021?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions), today reported financial results for the third quarter |
|
| November 4, 2021 |
Release Agreement by and between Treace Medical Concepts, Inc. and Dipak A. Rajhansa EXHIBIT 10.1 RELEASE AGREEMENT In return for payment of severance benefits pursuant to the Change in Control Severance Agreement between Treace Medical Concepts, Inc., and me (the ?CIC Severance Agreement?), I hereby generally and completely release Treace Medical Concepts, Inc. (?Treace?), its parent and subsidiary entities (collectively the ?Company?), and its or their directors, officers, emplo |
|
| October 4, 2021 |
Treace Medical Concepts Appoints New Directors Exhibit 99.1 Treace Medical Concepts Appoints New Directors PONTE VEDRA, Fla. ? October 4, 2021?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today announced the appointment of Betsy Hanna and Deepti Jain to its Board o |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (C |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ?QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ?TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40355 Treace M |
|
| August 5, 2021 |
Treace Medical Concepts Reports Second Quarter 2021 Financial Results Exhibit 99.1 Treace Medical Concepts Reports Second Quarter 2021 Financial Results PONTE VEDRA, Fla. ? August 5, 2021?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the second quarter |
|
| August 5, 2021 |
EXHIBIT 10.6 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of 5/21/2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and DIPAK A. RAJHANSA (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control (as |
|
| August 5, 2021 |
EXHIBIT 10.5 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of 5/27/2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and JOE W. FERGUSON (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control (as de |
|
| August 5, 2021 |
Exhibit 10.7 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of 5/23/2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and SEAN F. SCANLAN (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control (as de |
|
| August 5, 2021 |
EXHIBIT 10.4 Change in Control Severance Agreement This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of 5/25/2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the ?Company?), and DANIEL E. OWENS (the ?Executive?). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a potential Change in Control (as de |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 TREACE MEDICAL CONCEPTS, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commi |
|
| May 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| May 25, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40355 47-1052611 (State or other jurisdiction of incorporation) (Commiss |
|
| May 25, 2021 |
Treace Medical Concepts Reports First Quarter 2021 Financial Results Exhibit 99.1 Treace Medical Concepts Reports First Quarter 2021 Financial Results PONTE VEDRA, Fla. ? May 25, 2021?Treace Medical Concepts, Inc. (?Treace? or the ?Company?) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgus (commonly known as bunions), today reported financial results for the first quarter end |
|
| May 25, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| April 27, 2021 |
Amended and Restated Certificate of Incorporation of Treace Medical Concepts, Inc. EX-3.1 2 d178909dex31.htm EX-3.1 Exhibit 3.1 TREACE MEDICAL CONCEPTS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Treace Medical Concepts, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the Corporation is Treace Medical Concepts, Inc. The original Certificate of Incorpor |
|
| April 27, 2021 |
2021 Incentive Award Plan and related form agreements. Exhibit 99.2 TREACE MEDICAL CONCEPTS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrase |
|
| April 27, 2021 |
2021 Employee Stock Purchase Plan. EX-99.3 5 d138051dex993.htm EX-99.3 Exhibit 99.3 TREACE MEDICAL CONCEPTS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Compan |
|
| April 27, 2021 |
Amended and Restated Bylaws of the Treace Medical Concepts, Inc. EX-3.2 3 d178909dex32.htm EX-3.2 Exhibit 3.2 Amended and Restated Bylaws of Treace Medical Concepts, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures for Business Brought before a Mee |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40355 47- 1052611 (State or other jurisdiction of incorporation) (Comm |
|
| April 27, 2021 |
As filed with the Securities and Exchange Commission on April 27, 2021 Registration No. |
|
| April 26, 2021 |
11,250,000 Shares Common Stock Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-254863 and 333-255451 11,250,000 Shares Common Stock This is an initial public offering of shares of common stock by Treace Medical Concepts, Inc. We are offering 6,250,000 shares of our common stock to be sold in the offering. The selling stockholders identified in this prospectus are offering an additional 5,000,000 shares |
|
| April 22, 2021 |
As filed with the Securities and Exchange Commission on April 22, 2021 Registration No. |
|
| April 20, 2021 |
Treace Medical Concepts, Inc. 203 Fort Wade Rd., Suite 150 Ponte Vedra, Florida 32081 CORRESP 1 filename1.htm Treace Medical Concepts, Inc. 203 Fort Wade Rd., Suite 150 Ponte Vedra, Florida 32081 April 20, 2021 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Michael Fay Terence O’Brien Abby Adams Christopher Edwards Re: Treace Medical Concepts, Inc. Registration Statement |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identifica |
|
| April 20, 2021 |
April 20, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 19, 2021 |
Change in Control Severance Agreement by and between Treace Medical Concepts, Inc. and Mark Hair EX-10.6 10 d111748dex106.htm EX-10.6 Exhibit 10.6 CHANGE IN CONTROL SEVERANCE AGREEMENT This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and MARK L. HAIR (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event |
|
| April 19, 2021 |
140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris April 19, 2021 Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. M |
|
| April 19, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 Treace Medical Concepts, Inc. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Treace Medical Concepts, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as |
|
| April 19, 2021 |
2021 Incentive Award Plan and related form agreements EX-10.3 9 d111748dex103.htm EX-10.3 Exhibit 10.3 TREACE MEDICAL CONCEPTS, INC. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the |
|
| April 19, 2021 |
Amended and Restated Bylaws of the Registrant, to be in effect upon the completion of this offering. EX-3.4 5 d111748dex34.htm EX-3.4 Exhibit 3.4 Amended and Restated Bylaws of Treace Medical Concepts, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Advance Notice Procedures for Business Brought before a Mee |
|
| April 19, 2021 |
EX-10.7 11 d111748dex107.htm EX-10.7 Exhibit 10.7 CHANGE IN CONTROL SEVERANCE AGREEMENT This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and Jaime A. Frias (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the even |
|
| April 19, 2021 |
Exhibit 3.2 TREACE MEDICAL CONCEPTS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Treace Medical Concepts, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the Delaware General Corporation Law, hereby certifies as follows: The name of the Corporation is Treace Medical Concepts, Inc. The original Certificate of Incorporation of the Corporation was file |
|
| April 19, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 Treace Medical Concepts, Inc. [●] Shares of Common Stock, par value $0.001 per share Underwriting Agreement [●], 2021 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 |
|
| April 19, 2021 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on April 19, 2021. Registration No. 333-254863 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 3841 47-1052611 (State or othe |
|
| April 19, 2021 |
EX-10.13 13 d111748dex1013.htm EX-10.13 Exhibit 10.13 CHANGE IN CONTROL SEVERANCE AGREEMENT This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of April 19, 2021, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and John T. Treace (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the |
|
| April 19, 2021 |
Form of Common Stock Certificate EX-4.2 6 d111748dex42.htm EX-4.2 Exhibit 4.2 Exhibit 4.2 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE SEE REVERSE FOR CERTAIN DEFINITIONS AND LEGENDS This certifies that is the record holder of FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF TREACE MEDICAL CONCEPTS, INC. transferable on the books of the Corporation in person or by duly authorized attorne |
|
| April 19, 2021 |
2021 Employee Stock Purchase Plan. Exhibit 10.11 TREACE MEDICAL CONCEPTS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan co |
|
| April 19, 2021 |
Form of Indemnification Agreement for directors and executive officers. EX-10.1 8 d111748dex101.htm EX-10.1 Exhibit 10.1 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (“Agreement”) is made as of , 20 by and between Treace Medical Concepts, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/an officer/an employee] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and |
|
| March 30, 2021 |
Amended and Restated Certificate of Incorporation, as currently in effect. Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1. The jurisdiction where the Limited Liability Company first formed is the State of Florida. 2. The jurisdiction immediately prior to filing this Certificate is the State of Florida. 3. The date the Limited Liability Company firs |
|
| March 30, 2021 |
Bylaws, as amended, of the Registrant, as currently in effect. EX-3.3 3 d111748dex33.htm EX-3.3 Exhibit 3.3 BYLAWS OF TREACE MEDICAL CONCEPTS, INC. Article I. Offices The registered office of the corporation, as required by the Delaware General Corporation Law, in the State of Delaware shall be in the City of Wilmington, County of New Castle, and the address of the registered office may be changed from time to time by the board of directors. The corporation s |
|
| March 30, 2021 |
140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris March 30, 2021 Dubai Riyadh D?sseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo Madrid Washington, D.C. M |
|
| March 30, 2021 |
Form of Product Development Royalty Agreement. EX-10.12 15 d111748dex1012.htm EX-10.12 Exhibit 10.12 [name of consultant] PRODUCT DEVELOPMENT ROYALTY AGREEMENT This Product Development Royalty Agreement (“Agreement”) is entered into effective this day of , 20 (“Effective Date”), by and between Treace Medical Concepts, Inc., a Delaware corporation with its principal office located at 203 Fort Wade Rd. Suite 150, Ponte Vedra, FL 32081, along wit |
|
| March 30, 2021 |
Form of Notice of Option Exercise under 2014 Stock Plan. EX-10.2(D) 7 d111748dex102d.htm EX-10.2(D) Exhibit 10.2(d) 2014 STOCK PLAN FORM OF EXERCISE NOTICE Treace Medical Concepts, Inc. 203 Fort Wade Rd., Suite 150 Ponte Vedra, FL 32081 Attention: Chief Financial Officer 1. Exercise of Option. Effective as of , the undersigned (“Optionee”) hereby elects to exercise Optionee’s option (the “Option”) to purchase shares of Class A Common Stock (the “Shares” |
|
| March 30, 2021 |
Offer Letter Agreement by and between the Registrant and Jaime A. Frias, dated as of June 8, 2017. Exhibit 10.10 Job Offer Summary VP, General Counsel, Secretary & Compliance Officer Jim Frias Title and Job Summary: Reporting to the CEO, the VP, General Counsel, Secretary & Compliance Officer is responsible for: the management and execution of general corporate legal and compliance matters and activities for the Company; directing the legal affairs of the Company; managing outside counsel and d |
|
| March 30, 2021 |
Exhibit 10.9 September 11, 2020 Job Offer Summary Chief Financial Officer (“CFO”) Mark Hair Dear Mark, It is with great pleasure that Treace Medical Concepts, Inc. (“Treace” or the “Company”) offers you the full-time exempt position of Executive Vice President & Chief Financial Officer (CFO). You will be reporting to John T. Treace, CEO, and your proposed scheduled start date is September 21, 2020 |
|
| March 30, 2021 |
Exhibit 10.2(a) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN 1. Purposes of the Plan. The name of this plan is the Treace Medical Concepts, Inc. 2014 Stock Plan (the ?Plan?). The purposes of this Plan are to (a) attract and retain the best available personnel for positions of substantial responsibility; (b) to provide additional incentive to Employees, Directors and Consultants; and (c) to promot |
|
| March 30, 2021 |
Severance Agreement by and between the Registrant and Mark L. Hair, dated as of October 5, 2020. EX-10.6 10 d111748dex106.htm EX-10.6 Exhibit 10.6 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT is dated October 5, 2020, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and MARK HAIR (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates, the Company desires to enter into this Severance Agreeme |
|
| March 30, 2021 |
EX-10.7 11 d111748dex107.htm EX-10.7 Exhibit 10.7 CHANGE IN CONTROL SEVERANCE AGREEMENT This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of October 5, 2020, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and Jaime A. Frias (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the eve |
|
| March 30, 2021 |
Table of Contents As filed with the U.S. Securities and Exchange Commission on March 30, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) Delaware 3841 47-1052611 (State or other jurisdiction of inco |
|
| March 30, 2021 |
EX-10.5 9 d111748dex105.htm EX-10.5 Exhibit 10.5 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 18, 2018 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank |
|
| March 30, 2021 |
Form of Stock Option Agreement for Directors under 2014 Stock Plan Exhibit 10.2(b) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2014 Stock Plan, as amended (the ?Plan?) shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to purchase Common Stock of the Company, subject |
|
| March 30, 2021 |
EX-10.4 8 d111748dex104.htm EX-10.4 Exhibit 10.4 TERM LOAN AGREEMENT dated as of July 31, 2020 among TREACE MEDICAL CONCEPTS, INC., as Borrower, the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, as Administrative Agent and Collateral Agent U.S. $50,000,000 TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 1.01 Certain Defined T |
|
| March 30, 2021 |
Form of Stock Option Agreement for Employees under 2014 Stock Plan EX-10.2(C) 6 d111748dex102c.htm EX-10.2(C) Exhibit 10.2(c) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2014 Stock Plan, as amended (the “Plan”) shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to pu |
|
| March 30, 2021 |
Severance Agreement by and between the Registrant and Robert P. Jordheim, dated as of July 31, 2020. Exhibit 10.8 SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (collectively with its Exhibits, this “Agreement”) is made between ROBERT P. JORDHEIM (“Employee”) and TREACE MEDICAL CONCEPTS, INC., and its affiliates, subsidiaries, parent, predecessors, successors and assigns (collectively and individually, “Company”). A. REASONS FOR AGREEMENT 1. Employee is bei |
|
| February 12, 2021 |
TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN EX-10.2(A) 4 filename4.htm Exhibit 10.2(a) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN 1. Purposes of the Plan. The name of this plan is the Treace Medical Concepts, Inc. 2014 Stock Plan (the “Plan”). The purposes of this Plan are to (a) attract and retain the best available personnel for positions of substantial responsibility; (b) to provide additional incentive to Employees, Directors and Con |
|
| February 12, 2021 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION PURSUANT TO SECTION 265 OF THE DELAWARE GENERAL CORPORATION LAW 1. The jurisdiction where the Limited Liability Company first formed is the State of Florida. 2. The jurisdiction immediately prior to filing this Certificate is the State of Florida. 3. The date the Limited Liability Company firs |
|
| February 12, 2021 |
EX-10.4 8 filename8.htm Exhibit 10.4 TERM LOAN AGREEMENT dated as of July 31, 2020 among TREACE MEDICAL CONCEPTS, INC., as Borrower, the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, as Administrative Agent and Collateral Agent U.S. $50,000,000 TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 1.01 Certain Defined Terms 1 1.02 |
|
| February 12, 2021 |
CHANGE IN CONTROL SEVERANCE AGREEMENT EX-10.7 11 filename11.htm Exhibit 10.7 CHANGE IN CONTROL SEVERANCE AGREEMENT This CHANGE IN CONTROL SEVERANCE AGREEMENT is dated as of October 5, 2020, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and Jaime A. Frias (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates in the event of a pot |
|
| February 12, 2021 |
Exhibit 10.10 Job Offer Summary VP, General Counsel, Secretary & Compliance Officer Jim Frias Title and Job Summary: Reporting to the CEO, the VP, General Counsel, Secretary & Compliance Officer is responsible for: the management and execution of general corporate legal and compliance matters and activities for the Company; directing the legal affairs of the Company; managing outside counsel and d |
|
| February 12, 2021 |
EX-10.6 10 filename10.htm Exhibit 10.6 SEVERANCE AGREEMENT This SEVERANCE AGREEMENT is dated October 5, 2020, by and between TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (the “Company”), and MARK HAIR (the “Executive”). PURPOSE In order to induce the Executive to remain in the employment of the Company and its Affiliates, the Company desires to enter into this Severance Agreement (the “Ag |
|
| February 12, 2021 |
Job Offer Summary Chief Financial Officer (“CFO”) Mark Hair EX-10.9 13 filename13.htm Exhibit 10.9 September 11, 2020 Job Offer Summary Chief Financial Officer (“CFO”) Mark Hair Dear Mark, It is with great pleasure that Treace Medical Concepts, Inc. (“Treace” or the “Company”) offers you the full-time exempt position of Executive Vice President & Chief Financial Officer (CFO). You will be reporting to John T. Treace, CEO, and your proposed scheduled start |
|
| February 12, 2021 |
SEPARATION AGREEMENT AND GENERAL RELEASE EX-10.8 12 filename12.htm Exhibit 10.8 SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (collectively with its Exhibits, this “Agreement”) is made between ROBERT P. JORDHEIM (“Employee”) and TREACE MEDICAL CONCEPTS, INC., and its affiliates, subsidiaries, parent, predecessors, successors and assigns (collectively and individually, “Company”). A. REASONS FOR AG |
|
| February 12, 2021 |
Table of Contents Confidential Draft submitted to the Securities and Exchange Commission on February 12, 2021. |
|
| February 12, 2021 |
BYLAWS OF TREACE MEDICAL CONCEPTS, INC. Article I. Offices Exhibit 3.3 BYLAWS OF TREACE MEDICAL CONCEPTS, INC. Article I. Offices The registered office of the corporation, as required by the Delaware General Corporation Law, in the State of Delaware shall be in the City of Wilmington, County of New Castle, and the address of the registered office may be changed from time to time by the board of directors. The corporation shall also have and maintain an of |
|
| February 12, 2021 |
EX-10.5 9 filename9.htm Exhibit 10.5 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of April 18, 2018 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and TREACE MEDICAL CONCEPTS, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The partie |
|
| February 12, 2021 |
TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT EX-10.2(B) 5 filename5.htm Exhibit 10.2(b) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2014 Stock Plan, as amended (the “Plan”) shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to purchase Common St |
|
| February 12, 2021 |
2014 STOCK PLAN FORM OF EXERCISE NOTICE EX-10.2(D) 7 filename7.htm Exhibit 10.2(d) 2014 STOCK PLAN FORM OF EXERCISE NOTICE Treace Medical Concepts, Inc. 203 Fort Wade Rd., Suite 150 Ponte Vedra, FL 32081 Attention: Chief Financial Officer 1. Exercise of Option. Effective as of , the undersigned (“Optionee”) hereby elects to exercise Optionee’s option (the “Option”) to purchase shares of Class A Common Stock (the “Shares”) of Treace Medi |
|
| February 12, 2021 |
TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT EX-10.2(C) 6 filename6.htm Exhibit 10.2(c) TREACE MEDICAL CONCEPTS, INC. 2014 STOCK PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the 2014 Stock Plan, as amended (the “Plan”) shall have the same defined meanings in this Stock Option Agreement. I. NOTICE OF STOCK OPTION GRANT Name: Address: The undersigned Optionee has been granted an Option to purchase Common St |
